| |  Online-Ressource |
|---|
| Verfasst von: | Basset, Marco [VerfasserIn]  |
|---|
| | Kimmich, Christoph [VerfasserIn] |
|---|
| | Schreck, Nicholas [VerfasserIn] |
|---|
| | Krzykalla, Julia [VerfasserIn] |
|---|
| | Dittrich, Tobias [VerfasserIn] |
|---|
| | Veelken, Kaya [VerfasserIn] |
|---|
| | Goldschmidt, Hartmut [VerfasserIn] |
|---|
| | Seckinger, Anja [VerfasserIn] |
|---|
| | Hose, Dirk [VerfasserIn] |
|---|
| | Jauch, Anna [VerfasserIn] |
|---|
| | Müller-Tidow, Carsten [VerfasserIn] |
|---|
| | Benner, Axel [VerfasserIn] |
|---|
| | Hegenbart, Ute [VerfasserIn] |
|---|
| | Schönland, Stefan [VerfasserIn] |
|---|
| Titel: | Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis |
|---|
| Titelzusatz: | results from a large cohort of patients with long follow-up |
|---|
| Verf.angabe: | Marco Basset, Christoph R. Kimmich, Nicholas Schreck, Julia Krzykalla, Tobias Dittrich, Kaya Veelken, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Carsten Müller-Tidow, Axel Benner, Ute Hegenbart, and Stefan O. Schönland |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | 3 August 2021 |
|---|
| Umfang: | 14 S. |
|---|
| Fussnoten: | Gesehen am 14.08.2023 |
|---|
| Titel Quelle: | Enthalten in: British journal of haematology |
|---|
| Ort Quelle: | Oxford [u.a.] : Wiley-Blackwell, 1955 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 195(2021), 2, Seite 230-243 |
|---|
| ISSN Quelle: | 1365-2141 |
|---|
| Abstract: | Lenalidomide and dexamethasone (RD) is a standard treatment in relapsed/refractory immunoglobulin light chain (AL) amyloidosis (RRAL). We retrospectively investigated toxicity, efficacy and prognostic markers in 260 patients with RRAL. Patients received a median of two prior treatment lines (68% had been bortezomib-refractory; 33% had received high-dose melphalan). The median treatment duration was four cycles. The 3-month haematological response rate was 31% [very good haematological response (VGHR) in 18%]. The median follow-up was 56·5 months and the median overall survival (OS) and haematological event-free survival (haemEFS) were 32 and 9 months. The 2-year dialysis rate was 15%. VGHR resulted in better OS (62 vs. 26 months, P < 0·001). Cardiac progression predicted worse survival (22 vs. 40 months, P = 0·027), although N-terminal prohormone of brain natriuretic peptide (NT-proBNP) increase was frequently observed. Multivariable analysis identified these prognostic factors: NT-proBNP for OS [hazard ratio (HR) 1·71; P < 0·001]; gain 1q21 for haemEFS (HR 1·68, P = 0·014), with a trend for OS (HR 1·47, P = 0·084); difference between involved and uninvolved free light chains (dFLC) and light chain isotype for OS (HR 2·22, P < 0·001; HR 1·62, P = 0·016) and haemEFS (HR 1·88, P < 0·001; HR 1·59, P = 0·008). Estimated glomerular filtration rate (HR 0·71, P = 0·004) and 24-h proteinuria (HR 1·10, P = 0·004) were prognostic for renal survival. In conclusion, clonal and organ biomarkers at baseline identify patients with favourable outcome, while VGHR and cardiac progression define prognosis during RD treatment. |
|---|
| DOI: | doi:10.1111/bjh.17685 |
|---|
| URL: | kostenfrei: Volltext: https://doi.org/10.1111/bjh.17685 |
|---|
| | kostenfrei: Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.17685 |
|---|
| | DOI: https://doi.org/10.1111/bjh.17685 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | AL amyloidosis |
|---|
| | biomarkers |
|---|
| | gain 1q21 |
|---|
| | lenalidomide |
|---|
| | prognosis |
|---|
| K10plus-PPN: | 1856121968 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
| |
|
|---|
| | |
|---|
| Lokale URL UB: |  Zum Volltext |
|---|
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis / Basset, Marco [VerfasserIn]; 3 August 2021 (Online-Ressource)
